| Serial Number | 97255702 |
| Word Mark | 180 |
| Filing Date | Monday, February 7, 2022 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Thursday, June 27, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
| Description of Mark | The mark consists of the term "180" in a stylized block, shaded font, the "0" in "180" being bisected along an axis running from its lower left to its upper right with an outwards-pointing barb appearing on each half, and with two similar but smaller "0" characters at each of the lower left and the upper right of the "0" of "180". |
| Goods and Services | Analgesic preparations; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of inflammation; Pharmaceutical preparations for the treatment of Dupuytren's disease; Pharmaceutical preparations for the treatment of frozen shoulder; Pharmaceutical preparations for the treatment of post-operative delirium; Pharmaceutical preparations for the treatment of post-operative cognitive deficit; Pharmaceutical preparations for the treatment of post-operative cognitive decline; Pharmaceutical preparations for the treatment of non-alcoholic steatohepatitis; Pharmaceutical preparations for the treatment of fibrosis; Pharmaceutical preparations for the treatment of liver fibrosis; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of ulcerative colitis; Pharmaceutical preparations for the treatment of anxiety; Pharmaceutical preparations for the treatment of type 1 diabetes; Pharmaceutical preparations for the treatment of type 2 diabetes; Pharmaceutical preparations for inhibition of tumor necrosis factor (TNF); Pharmaceutical preparations for interacting with nicotine receptors; Pharmaceutical preparations for synthetically simulating non-psychoactive effects of cannabidiol (CBD); Pharmaceutical preparations for liver regeneration; Pharmaceutical preparations for regenerative therapy; Pharmaceutical preparations for acting as an alpha-7nAChR agonist |
| Pseudo Mark | ONE EIGHT ZERO; ONE HUNDRED EIGHT |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Goods and Services | Development of pharmaceutical preparations and medicines; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development in the pharmaceutical and biotechnology fields; Scientific research for medical purposes in the field of inflammatory diseases; Scientific research for medical purposes in the field of treatment of inflammation; Scientific research for medical purposes in the field of Dupuytren's disease; Scientific research for medical purposes in the field of frozen shoulder; Scientific research for medical purposes in the field of post-operative delirium, post-operative cognitive deficit, and post-operative cognitive decline; Scientific research for medical purposes in the field of non-alcoholic steatohepatitis; Scientific research for medical purposes in the field of fibrosis; Scientific research for medical purposes in the field of liver fibrosis; Scientific research for medical purposes in the field of arthritis; Scientific research for medical purposes in the field of pain treatment; Scientific research for medical purposes in the field of ulcerative colitis; Scientific research for medical purposes in the field of treatment of anxiety; Scientific research for medical purposes in the field of inhibition of tumor necrosis factor (TNF) and anti-TNF pharmaceuticals; Scientific research for medical purposes in the field of interactions with nicotine receptors; Scientific research for medical purposes in the field of synthetic simulation of non-psychoactive effects of cannabidiol (CBD); Scientific research for medical purposes in the field of synthetic cannabidiol (CBD) analogs; Scientific research for medical purposes in the field of type 1 diabetes; Scientific research for medical purposes in the field of type 2 diabetes; Scientific research for medical purposes in the field of liver regeneration; Scientific research for medical purposes in the field of regenerative therapy; Scientific research for medical purposes in the field of alpha-7nAChR agonists |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, February 11, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, February 11, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | 180 Life Sciences Corp. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Palo Alto, CA 94306 |
| Event Date | Event Description |
| Thursday, February 10, 2022 | NEW APPLICATION ENTERED |
| Friday, February 11, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, February 12, 2022 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Tuesday, July 18, 2023 | ASSIGNED TO EXAMINER |
| Monday, December 4, 2023 | ASSIGNED TO EXAMINER |
| Wednesday, December 6, 2023 | ASSIGNED TO EXAMINER |
| Wednesday, January 17, 2024 | ASSIGNED TO EXAMINER |
| Thursday, January 25, 2024 | NON-FINAL ACTION WRITTEN |
| Thursday, June 27, 2024 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Thursday, June 27, 2024 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Thursday, January 25, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, January 25, 2024 | NON-FINAL ACTION E-MAILED |